Company profile
SYNDAX PHARMACEUTICALS INC
NASDAQ:SNDXBiotechnology: Pharmaceutical Preparations
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| REVUFORJ | approved | $32.0MQ3 2025 | 0 | — |
| AXATILIMAB | phase2 | — | 5 | active |
| ENTINOSTAT | phase2 | — | 18 | completed, terminated, withdrawn |
| REVUMENIB SESQUIFUMARATE | phase1 | — | 1 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (29)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03238027 | phase1 | completed | 2017-09-01 | 2020-11-20 | Syndax Pharmaceuticals | A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors |
| NCT03604692 | phase1_2 | completed | 2018-11-01 | 2022-08-12 | Syndax Pharmaceuticals | A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD |
| NCT00750698 | phase2 | terminated | 2008-08-01 | 2010-05-01 | Syndax Pharmaceuticals | A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib |
| NCT00866333 | phase2 | terminated | 2009-04-13 | 2013-02-08 | Syndax Pharmaceuticals | A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma |
| NCT04415073 | phase2 | terminated | 2020-05-30 | 2020-07-13 | Syndax Pharmaceuticals | A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19 |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 218944 | 2024-11-15 | NDA | SYNDAX PHARMACEUTICALS INC | |||||
Loading… | ||||||||